Professional
Added to YB: 2026-07-22
Pitch date: 2026-07-18
FNCH [neutral]
Finch Therapeutics Group, Inc.
-5.16%
current return
Author Info
No bio for this author
Company Info
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Market Cap
$17.1M
Pitch Price
$10.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.87
P/E
-1.21
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Arquitos Capital Management Portfolio Holding: Finch Therapeutics Group, Inc.
FNCH.Q (holding update): Strategic Ch11 to sell co. Court ruled 5.5% royalty, $25.8M damages (no enhanced damages)—at/below low end of expectations. Bankruptcy auction won by Ferring; total sale $32M. Disappointing outcome, likely low double-digit return over 2yr hold. Downside was protected.
Read full article (1 min)